|
|
Article: Plasma-Based Drug Firm Talecris Seeking $1B IPO.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Talecris Biotherapeutics Holdings Corp., which was formed two years ago to cultivate the plasma-derived therapeutics business acquired from Bayer HealthCare LLC, is taking aim at the public market. The Research Triangle Park, N.C.-based firm filed for an initial public offering, with hopes of raising a whopping $1 billion.
Neither the number of shares nor the share price has been established. In its prospectus, the company said it plans to use proceeds to repay existing debt and cover unpaid dividends, with remaining money slated for working capital, capital expenditures and general corporate purposes including the acquisition of ...